Symetryx Corp is 10% Owner at NeuBase Therapeutics, Inc. (NBSE). They have made 3 open-market trades across 1 company since 2023, most recently 2023-09-18.
CIK 0001991925
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $120K since 2023, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NBSE | 50,000 | $19K |
Shares reported on the most recent Form 4, priced at the 2023-09-18 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.